13F Holdings
中文EN

ANAB ANAPTYSBIO, INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1370053 · Fiscal year ends 06/30

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY107.7%
TTM net income YoY81.0%
TTM EPS YoY78.1%
Revenue 3-yr CAGR179.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin35.9%
Net margin-11.5%
FCF margin1.9%
EBITDA margin36.0%

Returns

ROE-114.6%
ROA-7.1%
ROIC (approx.)—
Asset turnover0.62x

Leverage & solvency

Liabilities / assets96.1%
Debt / equity0.00x
Current ratio7.58x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.17x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$234.60M$91.28M$17.16M$10.29M$63.17M
R&D expense$135.97M$163.84M$132.28M$88.80M$98.50M
SG&A expense$11.35M$13.63M$41.95M$36.64M$21.49M
Operating income$226.90M$66.15M-$164.41M-$115.15M-$56.81M
Interest expense————$0
Pretax income$162.28M$31.14M-$163.62M-$128.70M-$57.80M
Income tax$772,000$158,000-$4,000$24,000$0
Net income-$13.23M-$145.23M-$163.62M-$128.72M-$57.80M
EBITDA$226.92M$66.17M-$163.76M-$114.48M-$56.20M
EPS (basic)-0.46-5.12-6.08-4.57-2.11
EPS (diluted)-0.44-4.92-6.08-4.57-2.11
Weighted avg. shares (diluted)30.23M29.54M26.92M28.16M27.43M
Balance sheet
Cash & equivalents$138.20M$23.08M$0$71.31M$495.73M
Short-term investments$73.44M$262.29M$354.94M$369.93M$52.37M
Receivables$33.85M$40.77M$6.85M$1.42M$876,000
Current assets$350.25M$431.88M$406.83M$447.20M$553.88M
PP&E, net$111,000$131,000$2.10M$2.09M$2.28M
Total assets$364.39M$483.83M$452.39M$610.38M$643.07M
Current liabilities$38.62M$45.43M$37.44M$26.05M$16.10M
Total liabilities$327.19M$412.97M$364.29M$348.28M$286.64M
Shareholders' equity$37.21M$70.87M$88.10M$262.10M$356.43M
Shares outstanding28.02M30.47M26.60M28.51M27.65M
Cash flow statement
Operating cash flow$19.70M-$135.34M-$120.80M-$73.59M-$45.92M
Capital expenditure$87,000$358,000$807,000$358,000$1.37M
Free cash flow$19.61M-$135.69M-$121.61M-$73.95M-$47.29M
Investing cash flow$228.03M$31.36M$144.75M-$394.85M$38.84M
Financing cash flow-$132.61M$127.05M-$59.30M$44.02M$252.30M
Depreciation & amortization$20,000$20,000$652,000$675,000$619,000
Stock-based compensation$3.77M$7.22M$33.20M$27.36M$15.35M
Share buybacks$68.63M$456,000$50.00M$0$0

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.